Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F08%3A00001283" target="_blank" >RIV/00216208:11120/08:00001283 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Original language description

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET- patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET- patients (95% confidence interval [CI], 94%-99%) and 86% for PET- patients (95% CI, 78%-95%, P = .011). The NPV forPET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET- patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remiss

Czech name

Pozitronový emisní tomograf má negativní prediktivní hodnoty pro progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu

Czech description

Autoři popisují negativní vliv pozitronového emisního tomografu na progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NR8033" target="_blank" >NR8033: Reduction of Toxicity in First-line Treatment of Advanced Stage Hodgkin´s Lymphoma</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2008

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

112

Issue of the periodical within the volume

10

Country of publishing house

US - UNITED STATES

Number of pages

6

Pages from-to

—

UT code for WoS article

000260691300016

EID of the result in the Scopus database

—